Reduction of HLA-DR+ lymphocytes after treatment with enzastaurin in patients with metastatic thyroid cancer.
Chemotherapy
; 54(4): 268-73, 2008.
Article
em En
| MEDLINE
| ID: mdl-18667816
ABSTRACT
BACKGROUND:
Cytotoxic anti-tumor agents like methotrexate or cyclophosphamide have been used in the treatment of autoimmune diseases although the exact mechanism of their immunomodulatory function is unclear. By contrast, molecularly targeted anti-tumor agents, such as the serine/threonine kinase inhibitor enzastaurin, have not been evaluated for treatments other than cancer.METHODS:
Blood was sampled from patients with metastatic thyroid cancer treated with enzastaurin followed by the combination treatment of enzastaurin and the anti-folate pemetrexed. During this sequential treatment, blood was drawn every 14 days to monitor changes in the lymphocyte population.RESULTS:
We observed that enzastaurin monotherapy reduced the number of HLA-DR-expressing lymphocytes. No signs of infection were observed in any patient.CONCLUSION:
Our findings suggest an immunomodulatory effect of enzastaurin in addition to the anti-tumor effect.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Glândula Tireoide
/
Linfócitos
/
Antígenos HLA-DR
/
Indóis
/
Antineoplásicos
Limite:
Humans
Idioma:
En
Ano de publicação:
2008
Tipo de documento:
Article